Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab versus rituximab in treatment-resistant rheumatoid arthritis
IRCT20230923059495N1Phase 2Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Aug 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in rheumatoid arthritis (RA) comparing Rituximab with Tocilizumab (2 arms). Primary endpoints: Comparison of the effects of tocilizumab and rituximab, Pain score and 2 more. Started Aug 2022; status: completed.
02
Drugs
tocilizumabrituximab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on IRCT20230923059495N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20230923059495N1.